EWA
MRNA icon

EP Wealth Advisors’s Moderna MRNA Stock Holding History

EP Wealth Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,385
Closed -$254K – 880
2024
Q1 		$254K Buy
+2,385
New +$240K ﹤0.01% 672
2023
Q4 		– Sell
-3,241
Closed -$335K – 829
2023
Q3 		$335K Buy
3,241
+2,007
+163% +$224K 0.01% 538
2023
Q2 		$387K Sell
1,234
-130,446
-99% -$17.4M 0.01% 513
2023
Q1 		$14M Buy
131,680
+129,736
+6,674% +$21.4M 0.24% 73
2022
Q4 		$349K Buy
+1,944
New +$318K 0.01% 436
2022
Q3 		– Sell
-1,930
Closed -$276K – 519
2022
Q2 		$276K Buy
1,930
+472
+32% +$67.5K 0.01% 496
2022
Q1 		$251K Sell
1,458
-314
-18% -$52.9K 0.01% 521
2021
Q4 		$450K Buy
1,772
+61
+4% +$17.8K 0.01% 375
2021
Q3 		$658K Buy
1,711
+60
+4% +$22.1K 0.02% 293
2021
Q2 		$388K Buy
+1,651
New +$295K 0.01% 385

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EP Wealth Advisors's MRNA Position: Q2 2024 in Review

EP Wealth Advisors sold out of Moderna (MRNA) in Q2 2024, closing a stake of 2,385 shares — an estimated $254K sold.

EP Wealth Advisors first reported a position in MRNA in Q2 2021 and held it in 10 quarters. The position peaked at $14M in Q1 2023. 954 funds tracked by Wall St. Rank hold MRNA as of Q2 2024.

  • EP Wealth Advisors reported no remaining Moderna position as of Q2 2024 after selling out during the quarter.
  • EP Wealth Advisors sold 2,385 Moderna shares in Q2 2024, an estimated $254K.
  • EP Wealth Advisors first reported a position in Moderna in Q2 2021 and held it in 10 quarters.
  • EP Wealth Advisors's Moderna position peaked at $14M in Q1 2023.
  • 954 funds tracked by Wall St. Rank held Moderna as of Q2 2024.

Based on EP Wealth Advisors's 13F filing for Q2 2024, filed 19 Aug 2024.